Table 1.

Characteristics of human brain samples

“ABC” score	Gender	Age (yrs)	PMI (hh:mm)	Neuropathological changes
Not or low AD	M	70	16:30	Control
	M	76	11:30	AGD I
	M	66	7:00	Braak I, Thal 0, CERAD none
	F	68	13:00	Braak I-II, Thal 1, CERAD none
	F	70	5:00	Braak II, Thal 0, CERAD none, sparse hypoxia
Interm. AD	F	75	21:00	Braak III, Thal 3, CERAD moderate, SVD
	F	80	9:00	Braak III-IV, Thal 3, CERAD sparse
	M	73	4:20	Braak III, Thal 5, CERAD frequent, CAA sparse
	F	79	4:30	Braak IV, Thal 4, CERAD moderate, AGD III
	M	79	5:30	Braak IV, Thal 5, CERAD frequent, CAA sparse, SVD
High AD	M	79	6:25	Braak VI, Thal 4, CERAD frequent, CAA sparse
	F	76	10:00	Braak VI, Thal 5, CERAD frequent, CAA severe
	M	75	10:00	Braak VI, Thal 5, CERAD frequent, CAA sparse, LBD
	F	77	19:00	Braak VI, Thal 5, CERAD frequent, CAA sparse, HS
	F	74	14:30	Braak VI, Thal 5, CERAD frequent, CAA severe, LBD

Individuals are diagnosed according the “ABC” score, which incorporates histopathologic assessments of amyloid β deposits (A, Thal phase for Aβ plaques), the staging of neurofibrillary tangles (B, Braak and Braak NFT stage), and scoring of neuritic plaques (C, CERAD neuritic plaque score). Results are transformed into one of four levels of AD neuropathologic change: Not, Low, Intermediate, or High AD. AGD argyrophilic grain disease, CAA cerebral amyloid angiopathy, HS Hippocampal sclerosis, LBD Lewy bodies disease, PMI post-mortem interval, SVD small vessel disease